false
Catalog
Co-occurring Opioid and Stimulant Use Disorders: T ...
Recording
Recording
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
In this video, two doctors, Dr. Craig Allen and Dr. Mark Fishman, discuss the treatment and management approaches for co-occurring opioid and stimulant use disorders. They begin by introducing the webinar and providing some housekeeping items. They then discuss the scope of the problem, focusing on opioid overdose deaths and the rise of fentanyl in the drug supply. They also discuss the prevalence of substance use disorders and the use of methamphetamine and cocaine in the United States. The doctors highlight the dangers of combining opioids and stimulants, and how it can increase the risk of overdose. They also discuss various medications and treatments for co-occurring opioid and stimulant use disorders, including agonist substitution strategies, prescription stimulants, topiramate, naltrexone, bupropion, and disulfiram. They also address the use of psychosocial treatments such as the matrix model and contingency management. The doctors then interview a patient named Jonathan, who shares his struggles with addiction to opioids and stimulants. He discusses his experiences with various medications, including Vivitrol and Suboxone, and how they affected him. Jonathan also talks about his interactions with the medical field and the challenges he faced. The video concludes with a summary of the medications and treatment approaches discussed, as well as information about resources offered by the Providers' Clinical Support System (PCSS).
Asset Subtitle
View the recorded presentation to attest that you have viewed the presentation in its entirety.
Keywords
co-occurring
opioid use disorders
stimulant use disorders
treatment
medications
dangers
overdose
psychosocial treatments
addiction
resources
The content on this site is intended solely to inform and educate medical professionals. This site shall not be used for medical advice and is not a substitute for the advice or treatment of a qualified medical professional.
Funding for this initiative was made possible by cooperative agreement no. 1H79TI086770 and grant no. 1H79TI085588 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.
PCSS-MOUD
PCSS-MOUD.org
pcss@aaap.org
8-Hour DEA Training Inquiries, email
PCSS-MOUD
.
ORN
opioidresponsenetwork.org
×
Please select your language
1
English